GrantN43
NOMOCAN PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS SBIR CONTRACTPHASE I - DEVELOPMENT OF THERAPEUTIC OR PRE
- Activity
- N43
- Fiscal years counted
- 2025
- Amount counted
- $854,107
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Abstract public domain (NIH RePORTER)
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related deaths by 2030 with a 5-year overall survival rate is only about 13%. For the majority of PDAC patients with metastatic PC, the current standard of care is systemic chemotherapy, which only extends survival by a few months. There is a critical need for less toxic, more potent targeted therapeutics for PDAC. Details in Aims